Comparative pharmacokinetics of single-dose administration of mammalian and bacterially-derived recombinant human granulocyte-macrophage colony-stimulating factor-Reference-Cited by-同舟云学术

Comparative pharmacokinetics of single-dose administration of mammalian and bacterially-derived recombinant human granulocyte-macrophage colony-stimulating factor

Published:2009-04-24 Issue:1 Volume:50 Page:32-36
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:

Author:

Hovgaard Doris,Mortensen Børge Thing,Schifter Søren,Nissen Nis I.

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0609.1993.tb00071.x/fullpdf

Reference23 articles.

1. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome;Groopman;N Engl J Med,1987

2. A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma;DeVries;Cancer Res,1991

3. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer;Nemunaitis;N Engl J Med,1992

4. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia;Bettelheim;Blood,1992

5. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation;Gianni;Lancet,1989

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetic and pharmacodynamic considerations in the development of biotechnology products and large molecules;Atkinson's Principles of Clinical Pharmacology;2022

2. Randomised controlled trial of GM-CSF in critically ill patients with impaired neutrophil phagocytosis;Thorax;2018-07-31

3. Assessing the Impact of Tissue Target Concentration Data on Uncertainty in In Vivo Target Coverage Predictions;CPT: Pharmacometrics & Systems Pharmacology;2016-10

4. A mechanistic PK/PD model for two anti-IL13 antibodies explains the difference in total IL-13 accumulation observed in clinical studies;mAbs;2016-04-06

5. Pharmacokinetic and Pharmacodynamic Considerations in the Development of Biotechnology Products and Large Molecules;Principles of Clinical Pharmacology;2012